Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,042 total articles
Strata Critical Medical offers asymmetric upside as the company converts recent operational improvements into sustainable EBITDA growth. We like the risk/reward here: enter at $3.50 with a $8.00 target and a $2.20 stop. The trade is driven by margin expansion, product adoption in hospital networks, and several near-term catalysts that can re-rate t…
Western Digital (WDC) has re-rated sharply but still offers a pragmatic long opportunity tied to the AI-driven NAND cycle. Strong profitability, healthy cash generation, and exposure to SanDisk's explosive NAND demand — coupled with a credible plan to monetize the spin-off stake — create a favorable asymmetric trade. Entry, stop and target provided…
Broadcom posted blockbuster Q1 FY2026 results with $19.3B revenue and $8.4B of AI-driven semiconductor sales, yet trades at roughly $1.52T market cap and a P/E in the low-60s. Strong margins, $29B of free cash flow and a clear path to $100B in AI revenue for 2027 argue for substantial upside. This trade idea lays out an actionable long with entry, …
NeXGold has spent years under the radar while building prospective drill targets and preserving shareholder capital. With gold fundamentals constructive and a series of near-term catalysts expected to reprice the story, we favor a tactical long. Entry: $1.20, Target: $2.50, Stop: $0.80. Trade horizon: long term (180 trading days).
American Integrity Insurance Group (AII) looks inexpensive relative to its profitability and cash generation. With a market cap near $375M, zero net debt, FCF of $51.7M and an EV/EBITDA of 2.4, the stock offers an asymmetric risk/reward for a mid-term swing. Trade plan below targets a run toward the 52-week high while keeping risk tight given opera…
Grab ($GRAB) has turned profitable, is scaling financial services, and is trading well below prior highs after a 2025-2026 pullback. With a $15.7B market cap, improving unit economics, active buyback authorization and expanding automation/capital-light initiatives, this is an actionable long trade for patient investors who want exposure to Southeas…
Standard Lithium just cleared two headline milestones: a binding Trafigura offtake for 8,000 tpa and >$1 billion in project debt indications for the South West Arkansas (SWA) project. The stock is digesting those wins after a pullback; with a sub-$1.0B market cap and clear near-term catalysts, this is a defined-risk, mid-term long trade.
Ternium offers a rare combination of a double-digit yield alternative (7.08% yield), a low price-to-book multiple (PB ~0.63) and cyclical upside if steel demand improves. The stock trades below its short- and medium-term moving averages and shows oversold technicals, creating a disciplined long entry for investors who can tolerate cyclicality and l…
UFP Industries (UFPI) looks attractively priced today. At $90.65 the stock trades at ~18x next-year EPS, EV/EBITDA ~8.3 and a market cap near $5.13B, while generating $276M of free cash flow and carrying almost no net leverage. Technicals show oversold conditions and short interest remains meaningful - a setup for a rebound if the industry stabiliz…
Qualcomm is trading well below its 52-week highs after the sector sell-off, but fundamentals remain intact: high free cash flow ($12.93B), a mid-20s P/E, a 2.7% yield and attractive EV/EBITDA of ~11. I lay out an actionable long trade with entry, stop and target and the reasons I'll keep adding on weakness over a 180-trading-day horizon.
ImmunityBio's Anktiva is transitioning from clinical validation to commercial scale. Recent EU approval, NCCN guideline inclusion and stronger-than-expected sales place upside within reach, but valuation and execution risks are non-trivial. This trade idea lays out an actionable long with entry, stop and targets across a mid-term horizon.
I am upgrading Palantir (PLTR) from Hold to Buy. The combination of sustained AI-driven demand, improving free cash flow ($2.10B trailing), a technically constructive setup, and manageable short interest creates an asymmetric trade opportunity. The valuation is rich, but recent operational proof points and catalysts justify a disciplined swing trad…
Wintrust Financial (WTFC) looks like a practical mid-term long: reasonable valuation (P/E ~12, P/B ~1.26), $1.10B in free cash flow, a freshly raised dividend and an RSI flirting with oversold. We lay out an entry at $130.00, a stop at $122.00 and a $150 target over ~45 trading days, with clear risk management and alternative horizons.
SMH has rallied sharply since last year's lows but remains supported by accelerating semiconductor demand tied to AI infrastructure and equipment spending. With a $44.3B market cap, a 52-week high at $427.94 and technicals sitting near key moving averages, I outline a swing trade to capture additional upside while containing downside with a strict …
MercadoLibre is down after an earnings miss and margin reinvestments, but fundamentals — $10.8B in free cash flow, 37%+ revenue growth cited in recent coverage, and a dominant fintech pipeline — argue for a long entry on weakness. This trade targets a recovery toward prior multiple expansion while keeping a tight stop for downside protection.
Roivant Sciences (ROIV) looks set to re-rate as clinical readouts and corporate de-risking converge. With a market cap near $20.2B, clear near-term catalysts (Q3 2026 rheumatoid arthritis data and continuing progress in the ulcerative colitis program), and improving technicals around rising 50-day support, I view ROIV as a strong buy for a long-ter…
Harrow is moving from niche compounding toward a broad ophthalmic platform. Management reaffirmed 2025 revenue of $270-$280M, is doubling multiple sales forces, and is integrating Melt Pharmaceuticals to extend procedural sedation reach. With heavy short interest and near-term technical oversold signals, this is a tradeable long targeting a re-rati…
Palantir has been punished by the market; underlying commercial traction and government backlog argue for a tactical long. This trade idea offers a mid-term swing plan with clear entry, target and stop while highlighting catalysts and the key risks that would flip the thesis.
Marvell just demonstrated that its role in AI infrastructure is more substantial than many investors realize. Strong fiscal Q4 results, aggressive FY2027 guidance, improving technicals, and a clean balance sheet support a mid-term long trade: entry $91.15, stop $80.00, target $120.00 over the next 45 trading days.
NervGen has a differentiated neuroregenerative approach that could change outcomes in demyelinating and peripheral nerve injury indications. The science is interesting and the stock can rally on positive data or partner news. However, the combination of a narrow cash runway, likely near-term financing, and binary clinical milestones makes the curre…
Rayonier's timberland portfolio and recent corporate actions make the stock an actionable swing trade. The market is underpricing the combination of recurring cash flow, a potential special return of capital and merger-driven upside. Entry at $20.25, stop at $19.20 and target at $24.00 for a mid-term trade (45 trading days).
Natera is trading near $200 with multiple oncology catalysts in motion: positive MRD data for Signatera, a strategic acquisition of Foresight Diagnostics, and growing market demand for esoteric and reproductive genetic tests. Fundamentals show improving free cash flow ($109.1M) and low leverage, but valuation is rich (P/S ~12, P/B ~16). This trade …
Kimberly-Clark offers a rare combination in 2026: a ~5% yield, steady free cash flow ($1.639B) and a strategically meaningful, deal-driven catalyst with the planned Kenvue acquisition. Valuation sits at ~16.5x trailing earnings and an enterprise value of roughly $39.8B, leaving room for upside if synergies materialize and pricing power holds. I out…
Broadcom's custom AI chips and networking franchises are powering an accelerating revenue mix; recent quarterly flows and management guidance show the AI cycle is already material to the top line. With $28.9B in annual free cash flow and a market cap near $1.5T, AVGO is expensive but priced for sustained AI-led earnings growth — we recommend a tact…
Micron (MU) is trading with momentum after a strategic fab purchase and ahead of a volatile earnings print. With sold-out HBM capacity through 2026, improving margins, $4.65B in free cash flow, and bullish technicals, the stock looks tradeable on the long side into the next quarter. This plan lays out a mid-term trade (45 trading days) to capture p…
